The mechanism of action of capmatinib in the treatment of lung cancer

Capmatinib (Capmatinib) is a drug that targets those carrying the MET gene14 Targeted therapeutic drugs for advanced or metastatic non-small cell lung cancer (NSCLC) with exon skipping mutations (METex14). Understanding its mechanism of action is critical to understanding its therapeutic effects and side effects.

Capatinib specifically inhibits the activation of MET receptors, thereby interfering with the conduction of the MET signaling pathway, blocking the abnormal proliferation, migration and invasion of tumor cells, and achieving the effect of inhibiting tumor growth and spread. Its mechanism of action mainly includes the following aspects:

1.METReceptor Inhibition:Capatinib (Capatinib) can specifically bind to the activation site of the MET receptor, blocking HGFbinds with the MET receptor, thereby inhibiting the autophosphorylation and activation of the MET receptor, reducing the activation of its downstream signaling pathways, thereby inhibiting the growth and metastasis of tumor cells.

2.Inhibition of tumor cell proliferation and growth:METsignaling pathway plays an important role in regulating the proliferation and growth of tumor cells.The inhibitory effect of Capatinib (Capatinib) can effectively slow down the proliferation rate of tumor cells and inhibit the growth of tumors.

3.Inhibition of tumor cell migration and invasion: MET signaling pathway is also involved in regulating the migration and invasion process of tumor cells. Capatinib (Capatinib) can reduce the migration and invasion ability of tumor cells and block the metastasis process of tumors.

4.Reduce angiogenesis:METsignaling pathway also plays a certain role in tumor angiogenesis,Capatinib (Capatinib)The inhibitory effect can reduce the expression of vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis, blocking the blood supply of tumors, causing tumor cells to lack oxygen and nutrient supply, leading to tumor shrinkage and apoptosis.

In general,Capatinib (Capatinib) as a drug targeting the MET signaling pathway, inhibits the activation of the MET receptor and interferes with the conduction of the MET signaling pathway, thereby inhibiting biological processes such as proliferation, migration, invasion and angiogenesis of tumor cells, achieving the effect of inhibiting tumor growth and spread. This provides an effective treatment option for patients with advanced or metastatic NSCLC who carry METex14 mutations.